Brokerages expect that vTv Therapeutics Inc (NASDAQ:VTVT) will report sales of $1.26 million for the current fiscal quarter, according to Zacks. Two analysts have made estimates for vTv Therapeutics’ earnings, with the lowest sales estimate coming in at $10,000.00 and the highest estimate coming in at $2.50 million. vTv Therapeutics posted sales of $4.52 million in the same quarter last year, which suggests a negative year-over-year growth rate of 72.1%. The company is scheduled to announce its next quarterly earnings results on Wednesday, February 26th.
According to Zacks, analysts expect that vTv Therapeutics will report full year sales of $5.24 million for the current year, with estimates ranging from $2.77 million to $7.70 million. For the next year, analysts anticipate that the firm will post sales of $6.38 million, with estimates ranging from $2.75 million to $10.00 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side analysts that cover vTv Therapeutics.
vTv Therapeutics (NASDAQ:VTVT) last posted its earnings results on Wednesday, October 30th. The biotechnology company reported ($0.10) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.11) by $0.01. The company had revenue of $0.01 million during the quarter, compared to analyst estimates of $1.69 million.
Shares of NASDAQ:VTVT traded up $0.02 during trading on Monday, hitting $1.53. The company’s stock had a trading volume of 248,856 shares, compared to its average volume of 98,159. The business has a 50 day moving average price of $1.50 and a two-hundred day moving average price of $1.45. vTv Therapeutics has a fifty-two week low of $1.00 and a fifty-two week high of $3.50.
In other news, major shareholder Ronald O. Perelman acquired 1,369,863 shares of the firm’s stock in a transaction dated Tuesday, November 26th. The stock was acquired at an average cost of $1.46 per share, with a total value of $1,999,999.98. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, major shareholder Ronald O. Perelman acquired 606,061 shares of the firm’s stock in a transaction dated Wednesday, September 18th. The shares were purchased at an average cost of $1.65 per share, with a total value of $1,000,000.65. The disclosure for this purchase can be found here. In the last 90 days, insiders acquired 6,085,513 shares of company stock valued at $9,000,001. Insiders own 1.70% of the company’s stock.
Several institutional investors have recently added to or reduced their stakes in VTVT. BlackRock Inc. lifted its position in shares of vTv Therapeutics by 25.7% during the 2nd quarter. BlackRock Inc. now owns 65,031 shares of the biotechnology company’s stock worth $93,000 after purchasing an additional 13,305 shares during the last quarter. Wedbush Securities Inc. purchased a new stake in shares of vTv Therapeutics during the 3rd quarter worth $39,000. Finally, Virtu Financial LLC lifted its position in shares of vTv Therapeutics by 162.4% during the 3rd quarter. Virtu Financial LLC now owns 76,541 shares of the biotechnology company’s stock worth $119,000 after purchasing an additional 47,369 shares during the last quarter. 5.66% of the stock is owned by institutional investors and hedge funds.
About vTv Therapeutics
vTv Therapeutics Inc, a clinical-stage biopharmaceutical company, discovers and develops orally administered small molecule drug candidates to fill unmet medical needs. The company is developing Azeliragon, an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase II/III clinical trials for the treatment of mild Alzheimer's disease.
Further Reading: Momentum Indicators
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.